BioSpace News Archive

Fact.MR, a market research and competitive intelligence provider: Sales in the global medical superabsorbent polymers market are expected to surpass US$ 5.66 Bn by 2032, as per a detailed study published by Fact.MR.

Surge in the adoption of advanced technologies such as artificial intelligence across the healthcare sector and growing support by several government authorities for digitalization are some of the prime factors boosting the expansion of the global digital transformation in healthcare market during the forecast period of 2021 to 2031.

According to Transparency Market Research’s latest report on the global diabetes devices market for the historical period 2017–2018 and forecast period 2019–2027, increase in prevalence of diabetes, and increase in adoption of insulin pumps among type 1 diabetes patients are projected to drive the global diabetes devices market during the forecast period.

Wilmington, Delaware, United States, Transparency Market Research Inc.: The clinical risk grouping solutions market is anticipated to observe steady growth during the forecast period of 2021-2031.

Brii Biosciences Limited announced that TSB Therapeutics Co., Ltd., a joint venture majority-owned by the Company, is partnering with China Resources Pharmaceutical Commercial Group Co., Ltd. to advance stockpiling, channel distribution and hospital access for the Company’s long-acting neutralizing monoclonal antibody therapy, the amubarvimab/romlusevimab combination.

Wilmington, Delaware, United States, Transparency Market Research Inc.: Stocking Refurbished Medical Inventories Prepares Hospitals to Tackle COVID-19 Pandemic Coronavirus has exposed the vulnerability of healthcare systems worldwide.

Fact.MR, a market research and competitive intelligence provider - The global MRI Safe Implantable Defibrillator Devices market would reach US$ 890 Mn in 2022 and have a CAGR of 6.7% from 2022 to 2032.

Sequana Medical NV, a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, announces the appointment of Doug Kohrs as an independent Non-Executive Director of the Company.

Paragraf, the first company in the world to deliver a scalable approach to graphene electronic device manufacturing, announces a plan to develop a new generation of graphene-based, in-vitro diagnostic products that will give results within a few minutes.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that a phase III clinical trial for SINOVAC’s inactivated quadrivalent influenza vaccine was initiated in the Republic of Chile through a collaboration with the Pontificia Universidad Católica de Chile.